Coronavirus Update: Canadian Evusheld Supply Deal, Nuvaxovid EU Shipments
Plus, US Limits On Xevudy Use
The US places certain limits on the use of GSK's Xevudy, while Canada signs a supply deal for another antibody therapy, AstraZeneca's Evusheld. Meanwhile, Novavax starts EU shipments of its vaccine and the UK funds ConserV's pan-coronavirus vaccine.
You may also be interested in...
Coronavirus Notebook: 35 Generic Firms To Produce Pfizer’s Paxlovid, AZ’s Evusheld Gains UK & Australian Approval
Finland’s Rokote expects to begin clinical trials with its intranasal vaccine after the summer, while Australia’s ENA Respiratory has dosed the first patients in a Phase IIa study of its antiviral nasal spray.
US FDA Lowers Bar for Latest COVID Monoclonal Antibody Authorization
Lilly appeared to benefit from agency’s increased familiarity in treating COVID-19 with these types of biologics. Changing nature of the pandemic and the loss of utility of older antibodies due to the Omicron variant may have also played a role in the data required for latest EUA.
AstraZeneca Focuses On COVID-19 Antibody Approach After Year Of Vaccine Headwinds
During its fourth quarter earnings call, the UK-based major expressed hopes that its prophylactic antibody approach would fare better after its COVID-19 jab faced several obstacles in developed markets last year.